Epistem's expertise and knowledge of the gastrointestinal epithelium has been applied to several well established models of Inflammatory Bowel Disease (IBD). Epistem's IBD team has many years of experience, routinely running these models for a range of clients including Biotechnology, Pharmaceutical and Nutraceutical companies.
Inflammatory Bowel Disease is a collective term used to describe Crohn's disease and Ulcerative Colitis (UC). Both diseases exhibit similar clinical symptoms but result from different underlying pathologies. The inflammation associated with IBD is thought to be due to the inappropriate activation of the mucosal immune system in response to antigens.
Epistem's preclinical models replicate aspects of IBD in humans and can be used to generate target validation and mechanism of action data to confirm efficacy of novel therapeutic agents.